Drugs / GD2-targeted CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02919046 | Sep 2016 → Sep 2020 | — | Sinobioway Cell Therapy Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GD2-targeted CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02919046 ↗ |
| Action | Deplete | “the CAR-GD2-modified T cells can recognize and kill tumor cells in the body” NCT02919046 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T cell immunotherapy (CAR-T)” NCT02919046 ↗ |